FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to compounds of general formula 
or to its pharmaceutically acceptable salts, where W is cycloalkyl; Y is hydrogen or pharmaceutically acceptable saccharide of formula, 
or 
Z is hydrogen; Q is a substitute chosen from a group consisting from 
and each B, E, G, R, T and M is hydrogen.
EFFECT: invention refers to methods for preparing the compounds (A) and their salts, to the based pharmaceutical composition for treatment of cancers and the associated diseases, as well as to application of said compounds and their salts in making pharmaceutical preparations for prevention and treatment of cancers.
15 cl, 1 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG AND SALT THEREOF AND DIABETES THERAPEUTIC AGENT CONTAINING SAID COMPOUNDS | 2005 |
|
RU2394015C2 |
| PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | 2015 |
|
RU2701188C2 |
| SUBSTITUTED DERIVATIVES OF NUCLEOSIDE, A METHOD OF THEIR SYNTHESIS (VARIANTS), A DRUG, A METHOD OF TREATMENT AND PROPHYLAXIS | 1995 |
|
RU2130029C1 |
| SUBSTITUTED INDOLE COMPOUNDS AS REDUCING REGULATORS OF ESTROGEN RECEPTORS | 2017 |
|
RU2722441C2 |
| SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | 2011 |
|
RU2606514C2 |
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2797558C2 |
| FLUOROVINYLBENZAMIDE COMPOUND AS A PD-L1 IMMUNOMODULATOR | 2020 |
|
RU2789450C1 |
| COMPOUNDS | 2008 |
|
RU2461559C2 |
| HYDROXYPURINE COMPOUNDS AND WAYS OF THEIR USE | 2015 |
|
RU2673458C1 |
| DICYCLOAZAALKANE DERIVATIVES, METHODS FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINE | 2008 |
|
RU2487866C2 |
